The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | IL-21-expanded NK cells and BTK dependence in CLL
Max Yano, MD, Ohio State University, Columbus, OH, discusses the efficacy of IL-21 expanded natural killer (NK) cells for chronic lymphocytic leukemia (CLL) treatment and the significance of BTK dependence. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
